Skip to main content

Table 2 PTTG1IP and securin in breast carcinoma

From: PTTG1-interacting protein (PTTG1IP/PBF) predicts breast cancer survival

  All subtypes TNBC
n=401 n=96
Neg PTTG1IP (%) High securin (%) Cytoplasmic securin (%) Neg PTTG1IP (%) High securin (%) Cytoplasmic securin (%)
All patients 25.7 39.5 17.5 57.3 82.6 79.2
Nodal status
 Node - 22.3 43.4 7.9 38.5 36.5 47.9
 Node + 27.1 63.1 9.2 15.6 21.9 30.2
Tumour size
 <2cm 18.2 19.4 4.7 25.0 21.9 29.2
 ≥2cm 28.6 35.6 13.1 29.2 34.4 47.9
Histological grade
 I 8.8 11.5 1.7 0 0 0
 II 21.5 26.1 14.1 0 0 0
 III 49.4 64.2 25.2 100 100 100
Intrinsic classification
 Luminal 11.5 29.6 3.2    
 HER2-amplified 25.5 40.7 8.7    
 Triple-negative 63.8 62.7 11.9    
  1. The table summarizes for each patient group the fractions (%) of cases with immunoexpression patterns indicating aggressive course of disease (negative PTTG1IP, high securin expressiona and cytoplasmic securin expression). The results are presented separately for all subtypes of breast carcinomas (n=401) and for TNBCs (n=96) and in subgroups divided according to the established prognosticators of breast cancer
  2. aHigh securin expression: securin-positivity observed in ≥10% of cancer cells